The IPO of Kairos Pharma, Ltd is a significant event as it marks the company's entry into the public market. The set price of $4.00 per share and the focus on cancer therapeutics could attract investor interest, potentially driving the stock price up in the short term. The 180-day insider lock-up period is standard, indicating no immediate insider selling pressure.